IR BioSciences Announces Promising Data from Study of Its Compound
Homspera
Data Suggests
Homspera Shows Promise As an Adjuvant for Vaccinesagainst Avian Flu and Other Viruses SCOTTSDALE, Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- IRBioSciences Holdings, Inc. announced today that preliminary datafrom its influenza vaccine adjuvant study being performed inconjunction with GenPhar Inc. indicates
Homspera elevates hostimmune responsiveness above that induced by v...
ImmuneRegen BioSciences Announces Promising Data on Homspera
Suggesting Potential as a Co-Therapeutic Agent
Compound Could Be Utilized as an Adjuvant and Play Key Role in theTreatment of Influenza and Cancer SCOTTSDALE, Ariz., March 20, 2007 /PRNewswire-FirstCall/ --ImmuneRegen BioSciences, a wholly owned subsidiary of IRBioSciences Holdings, Inc. , announced today that data obtained bythe Company on its Substance P analog,
Homspera, suggests that thecompound has potential value as a co-therape...